IMU (ASX) Why IMU is a multi multi bagger

Originally posted by Watmighthavben: ↑

Let's recap, what happened last couple of weeks to see the drop from 10c to 7.5c:

Let's speak the truth. The market is strong, particularly in the biotech sector. Imugene management have consistently blamed macroeconomic conditions and volatility in the biotech sector for their underperformance. Now who do they blame?

Capital raises are taking place at a premium to the prevailing share price (i.e., ACW - ASX). Transparency is being afforded to shareholders visa vie the CEO's of biotech companies (i.e., NEU - ASX). Clear and concise details and information pertaining to clinical trials, the timeline for data releases and correspondence from regulators is the benchmark.

Conversely, having noted data would be released at major conferences, then having stated important clinical trial results were "COMING SOON" at such medical convention's, Imugene have failed to notify shareholders of results from scan after scan in a clinical trial they have noted they are prioritising. It goes without saying IMU investors are no longer interested in the one patient who attained a complete response in the ongoing Vaxinia (MAST) Trial. They are interested in the other 46 patients dosed in the trial. In particular the 20 patients remaining in treatment after multiple scans thus far.

The market hopped on board with Imugene in the company's initial capital raises. Investors were buoyed by Imugene's entry into the lucrative lung cancer market, with the company's PD1 Vaxx vaccine showing so much promise in its initial Phase 1 hit out. Though once again communication from management has been found wanting, as the PD1 Vaxx combination trial with Roche Therapeutics Tercentriq has not been spoken of for close to a year now, since it entered the clinic.

Unfortunately Leslie Chong, Paul Hopper and the IMU board in general only have themselves to blame for their recent fall from grace, having shown so much promise in November 2023. In retrospect how they failed to capitalise on such stellar results from their Vaxinia (MAST) Trial back then is beyond me. It's only a matter of time before the majority say they aren't prepared to pay Monil Shah and other company representatives anymore. That they as shareholders and owners of the company made a mistake in delivering such generous bonuses and options to their otherwise well paid company representative's. Its surely only a matter of time before they stand up and say they aren't prepared any longer to throw good money after bad. Before they vote to out source the duties internal personnel have failed to deliver on. That's simply put, corporate life. Whilst some may be present to win friends and influence people, on the whole most on a share register are there to make money, irrespective of whose head has to role in between times.

There is much as always to look forward to for those remaining with skin in the game at Imugene (IMU - ASX). But now IMU shareholders must reassess. Management have consistently said they are unaware of why their share price is performing so poorly. They have even suggested at investor conferences and roadshows it is not their duty to sell shares to us as individuals, nor to deliver a strong share price. This has no doubt created a sense of uncertainty amongst the investment community at large.

Given the lack of information at hand it's all about keeping the faith, following the science and continuing to believe there are brighter days ahead, for those who hold and remain steadfast to the cause. If only the goal posts didn't keep changing they may have something to hold onto.

DYOR Seek investment advice as and when required Opinions only

Expand

Hi Ben,
The communication has been lacking, is that good or bad - who knows.
I bought into the last raise on the back of YF commenting that the CF33 is working exactly like it did in the lab and on rat or mice - the exact wording escapes me but I believed what he said, then with LC in the interviews everything seemed ok.
But is it really ok, or are we all part of a royal screw job, where there is almost at this point 1 share for everyone on the planet, imagine that - everyone you see everyday could be a share holder in this, so is or could this be the next millionaire and retirement maker - who knows.

No.	Vol.	Price($)
9	749749	5.3¢

No.

Vol.

Price($)

749749

5.3¢

Price($)	Vol.	No.
5.4¢	452962	3

Price($)

Vol.

No.

5.4¢

452962

No.	Vol.	Price($)
9	749749	0.053
16	2232390	0.052
23	3870053	0.051
48	3817390	0.050
18	2308452	0.049

No.

Vol.

Price($)

749749

0.053

2232390

0.052

3870053

0.051

3817390

0.050

2308452

0.049

Price($)	Vol.	No.
0.054	452962	3
0.055	821960	9
0.056	851531	5
0.057	591030	6
0.058	1285000	8

Price($)

Vol.

No.

0.054

452962

0.055

821960

0.056

851531

0.057

591030

0.058

1285000

(20min delay)
Last 5.3¢		Change -0.002(3.64%)		Mkt cap ! $389.5M

Open	High	Low	Value	Volume
5.6¢	5.6¢	5.3¢	$521.9K	9.645M

Hi Ben,The communication has been lacking, is that good or bad -...

Cokal plans to kick off unexpected underground mine in Indonesia

Bitcoin: Current State of Play & Where to Next | Swyftx

Sarytogan promises good returns on Kazakhstan project, but the market is uncertain

Emerald & Azure score Digger & Dealer awards

Finding financial stability when inflation's out of control

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Hi Ben,The communication has been lacking, is that good or bad -...

Top Stories

Cokal plans to kick off unexpected underground mine in Indonesia

Bitcoin: Current State of Play & Where to Next | Swyftx

Sarytogan promises good returns on Kazakhstan project, but the market is uncertain

Emerald & Azure score Digger & Dealer awards

Finding financial stability when inflation's out of control

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News